1. Home
  2. RPRX

RPRX

Royalty Pharma plc

Logo Royalty Pharma plc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Founded: 1996 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 12.3B IPO Year: 2020
Target Price: $46.75 AVG Volume (30 days): 2.7M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: 2.98% Dividend Payout Frequency: Quarterly
EPS: 2.53 EPS Growth: 2430.00
52 Week Low/High: $25.92 - $36.67 Next Earning Date: 05-09-2024
Revenue: $2,354,554,000 Revenue Growth: 5.24%
Revenue Growth (this year): 13.74% Revenue Growth (next year): 9.41%

Share on Social Networks: